4//SEC Filing
Flynn Daniel Lee 4
Accession 0001209191-23-010488
CIK 0001654151other
Filed
Feb 16, 7:00 PM ET
Accepted
Feb 17, 4:04 PM ET
Size
10.5 KB
Accession
0001209191-23-010488
Insider Transaction Report
Form 4
Flynn Daniel Lee
Chief Scientific Officer
Transactions
- Sale
Common Stock
2023-02-16$15.10/sh−1,370$20,686→ 58,813 total - Award
Stock Option (Right to Buy)
2023-02-15+65,900→ 65,900 totalExercise: $15.48Exp: 2033-02-14→ Common Stock (65,900 underlying) - Award
Common Stock
2023-02-15+16,488→ 60,183 total
Holdings
- 230,435(indirect: By Trust)
Common Stock
- 91,020(indirect: By Trust)
Common Stock
Footnotes (3)
- [F1]The reporting person was awarded 16,488 Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in three equal installments on each of February 15, 2024, February 15, 2025 and February 15, 2026.
- [F2]This sale was to cover tax liabilities in the vesting of restricted stock.
- [F3]This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in equal monthly installments over four years, beginning on March 15, 2023.
Documents
Issuer
Deciphera Pharmaceuticals, Inc.
CIK 0001654151
Entity typeother
Related Parties
1- filerCIK 0001713712
Filing Metadata
- Form type
- 4
- Filed
- Feb 16, 7:00 PM ET
- Accepted
- Feb 17, 4:04 PM ET
- Size
- 10.5 KB